There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Avenue Therapeutics Inc (ATXI), Immunomedics (IMMU) and Seattle Genetics (SGEN) with bullish sentiments.
Avenue Therapeutics Inc (ATXI)
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Avenue Therapeutics Inc today and set a price target of $12. The company’s shares closed yesterday at $5.98.
According to TipRanks.com, Arce is a 4-star analyst with an average return of 6.9% and a 37.1% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Arcturus Therapeutics Ltd, and Melinta Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Avenue Therapeutics Inc with a $11 average price target.
See today’s analyst top recommended stocks >>
Immunomedics (IMMU)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Immunomedics, with a price target of $28. The company’s shares closed yesterday at $11.98, close to its 52-week low of $11.55.
Selvaraju noted:
“We have utilized a DCF-based assessment in valuing Immunomedics. Our valuation assessment ascribes a total risk- adjusted net present value (rNPV) of $5.45B to IMMU-132 across breast, urothelial and lung cancer.”
According to TipRanks.com, Selvaraju has currently no stars on a ranking scale of 0-5 stars, with an average return of -6.2% and a 24.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
Immunomedics has an analyst consensus of Strong Buy, with a price target consensus of $23, which is a 92.0% upside from current levels. In a report released yesterday, Cowen & Co. also maintained a Buy rating on the stock with a $30 price target.
Seattle Genetics (SGEN)
In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Seattle Genetics, with a price target of $98. The company’s shares closed yesterday at $67.86.
Fein noted:
“We reach a price target of $98 after adjusting new corporate tax rate, cash, and other program updates. The price target is based on a sum-of-parts NPV-DCF ($63.2 HL + $3.6 relapsed sALCL + $11.2 frontline PTCL + $17.7 platform + $2.9 cash). Key risks to achievement of our target price include trial failures, safety issues, regulatory delays, competition, and dilutive financing. Seattle Genetics Inc. June 4, 2019 H.C. WAINWRIGHT & CO.”
According to TipRanks.com, Fein is a 3-star analyst with an average return of 0.9% and a 40.2% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.
Currently, the analyst consensus on Seattle Genetics is a Moderate Buy with an average price target of $76.71.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
